Drug name - Bevyxxa
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7598276 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(4 years from now) | |
| CN102336702B | PORTOLA PHARMS INC | Xa Factor Inhibitor N - (5-Dichloro - -2 - Pyridyl)--2-[[4 - [(Dimethylamino) Iminomethyl] Benzoyl] Amino] -5 - Benzamide Of Pharmaceutical Salts And Polymorphs |
Nov, 2026
(4 years from now) | |
| CN102336702A | PORTOLA PHARMS INC | Xa Factor Inhibitor N-(5-Chloro--2-Pyridyl)--2-[[4-[(Dimethylamino) Methyl] Benzoyl] Amino]--5-Methoxy-Benzamide Of Pharmaceutical Salt And Polymorph |
Nov, 2026
(4 years from now) | |
| CN101304971A | PORTOLA PHARMS INC | Pharmaceutical Salts And Polymorphs Of A Factor Xa Inhibitor N-(5-Chloro-2- Pyridyl)-2-[[4-[(Dimethylamino)Iminomethyl]Benzoyl]Amino]-5-Methoxy-Benzamide |
Nov, 2026
(4 years from now) | |
| CN101304971B | PORTOLA PHARMS INC | Xa Factor Inhibitor N-(5-Chloro--2-Pyridyl)--2-[[4-[(Dimethylamino) Methyl] Benzoyl] Amino]--5-Methoxy-Benzamide Of Pharmaceutical Salt And Polymorph |
Nov, 2026
(4 years from now) | |
| IN319923B | PORTOLA PHARMS INC | Method Of Making A Factor Xa Inhibitor |
Nov, 2026
(4 years from now) | |
| IN201400546P2 | PORTOLA PHARMS INC | Method Of Making A Factor Xa Inhibitor |
Nov, 2026
(4 years from now) | |
| EP1948608B1 | PORTOLA PHARMS INC | Pharmaceutical Salts And Polymorphs Of N-(5-Chloro-2-Pyridinyl)-2-[[4-[(Dimethylamino)Iminomethyl]Benzoyl]Amino]-5-Methoxy-Benzamide , A Factor Xa Inhibitor |
Nov, 2026
(4 years from now) | |
| EP1948608A2 | PORTOLA PHARMS INC | Pharmaceutical Salts And Polymorphs Of N-(5-Chloro-2-Pyridinyl)-2-[[4-[(Dimethylamino)Iminomethyl]Benzoyl]Amino]-5-Methoxy-Benzamide , A Factor Xa Inhibitor |
Nov, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555023 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(4 years from now) | |
| US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(5 years from now) | |
| US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(8 years from now) | |
| US8404724 | PORTOLA PHARMS INC | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
Mar, 2031
(8 years from now) | |
Drugs and Companies using BETRIXABAN ingredient
Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); prophylaxis of venous thrombosis; Inhibiting coagulation
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 40MG | CAPSULE;ORAL | Discontinued |
| 80MG | CAPSULE;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.